Laboratorios Farmaceuticos Rovi (FRA:41L) Cyclically Adjusted FCF per Share: €1.03 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:41L Laboratorios Farmaceuticos Rovi SA FRA:41L
89 GF Score
Price €54.30
GF Value €51.18
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Laboratorios Farmaceuticos Rovi Cyclically Adjusted FCF per Share?

Laboratorios Farmaceuticos Rovi FRA:41L +1.40% 89 Cyclically Adjusted FCF per Share is €1.03 as of Mar. 2026. GuruFocus rates FRA:41L with a GF Score™ of 89/100 and a GF Value™ of €51.18 (Fairly Valued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Laboratorios Farmaceuticos Rovi's adjusted free cash flow per share for the three months ended in Mar. 2026 was €0.103. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €1.03 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Laboratorios Farmaceuticos Rovi's average Cyclically Adjusted FCF Growth Rate was 23.80% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 25.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Laboratorios Farmaceuticos Rovi was 275.60% per year. The lowest was 17.80% per year. And the median was 45.70% per year.

As of today (2026-07-16), Laboratorios Farmaceuticos Rovi's current stock price is €54.30. Laboratorios Farmaceuticos Rovi's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €1.03. Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Price-to-FCF of today is 52.72.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Laboratorios Farmaceuticos Rovi was 2670.00. The lowest was 53.62. And the median was 108.85.


Laboratorios Farmaceuticos Rovi  (FRA:41L) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=54.30/1.03
=52.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Laboratorios Farmaceuticos Rovi was 2670.00. The lowest was 53.62. And the median was 108.85.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Laboratorios Farmaceuticos Rovi Cyclically Adjusted FCF per Share Related Terms


Laboratorios Farmaceuticos Rovi Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Laboratorios Farmaceuticos Rovi's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Laboratorios Farmaceuticos Rovi Cyclically Adjusted FCF per Share Chart

Laboratorios Farmaceuticos Rovi Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.18 0.53 0.65 0.81 1.04

Laboratorios Farmaceuticos Rovi Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.84 0.84 0.93 1.04 1.03

FRA:41L vs ZTS, UTHR, VTRS: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laboratorios Farmaceuticos Rovi Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Price-to-FCF falls into.


FRA:41L
89GF Score
Laboratorios Farmaceuticos Rovi SA FRA:41L
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Laboratorios Farmaceuticos Rovi Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Laboratorios Farmaceuticos Rovi's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.103/129.8600*129.8600
=0.103

Current CPI (Mar. 2026) = 129.8600.

Laboratorios Farmaceuticos Rovi Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 0.133 100.333 0.172
201609 0.099 99.737 0.129
201612 0.087 101.842 0.111
201703 -0.230 100.896 -0.296
201706 0.159 101.848 0.203
201709 0.025 101.524 0.032
201712 0.007 102.975 0.009
201803 0.021 102.122 0.027
201806 -0.141 104.165 -0.176
201809 -0.151 103.818 -0.189
201812 -0.083 104.193 -0.103
201903 -0.343 103.488 -0.430
201906 -0.008 104.612 -0.010
201909 -0.266 103.905 -0.332
201912 -0.277 105.015 -0.343
202003 -0.057 103.469 -0.072
202006 -0.346 104.254 -0.431
202009 0.014 103.521 0.018
202012 0.518 104.456 0.644
202103 0.376 104.857 0.466
202106 0.995 107.102 1.206
202109 0.723 107.669 0.872
202112 -0.136 111.298 -0.159
202203 1.892 115.153 2.134
202206 1.078 118.044 1.186
202209 -0.155 117.221 -0.172
202212 0.661 117.650 0.730
202303 0.374 118.948 0.408
202306 0.277 120.278 0.299
202309 -0.169 121.343 -0.181
202312 0.614 121.300 0.657
202403 0.128 122.762 0.135
202406 0.088 124.409 0.092
202409 0.396 123.121 0.418
202412 0.875 124.753 0.911
202503 0.207 125.531 0.214
202506 -0.066 127.251 -0.067
202509 1.090 126.840 1.116
202512 1.101 128.400 1.114
202603 0.103 129.860 0.103

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €1.03 mean?
Laboratorios Farmaceuticos Rovi (FRA:41L) has a Cyclically Adjusted FCF per Share of €1.03 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Laboratorios Farmaceuticos Rovi and its competitors.
Is Laboratorios Farmaceuticos Rovi's Cyclically Adjusted FCF per Share too high?
Laboratorios Farmaceuticos Rovi's current Cyclically Adjusted FCF per Share is €1.03. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Cyclically Adjusted FCF per Share compare to ZTS and UTHR?
Laboratorios Farmaceuticos Rovi's Cyclically Adjusted FCF per Share of €1.03 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. Laboratorios Farmaceuticos Rovi's current Cyclically Adjusted FCF per Share is €1.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi (FRA:41L) is currently considered Fairly Valued. The stock's GF Value™ is €51.18, compared to a current price of €54.30 — trading 6.1% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €1.03. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (FRA:41L), the current Cyclically Adjusted FCF per Share is €1.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Laboratorios Farmaceuticos Rovi (FRA:41L) Overvalued in 2026?

Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued. The current stock price of €54.30 is trading 6.1% above its estimated GF Value™ of €51.18. GuruFocus considers Laboratorios Farmaceuticos Rovi to be Fairly Valued.

Key valuation signals for FRA:41L:

  • Cyclically Adjusted FCF per Share: €1.03
  • GF Value™: €51.18 vs. price of €54.30 (6.1% above fair value)
  • GF Score™: 89/100 with 1 warning sign

No single metric tells the full story. See the FRA:41L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Laboratorios Farmaceuticos Rovi Business Description

Address Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
89GF Score

Get the complete analysis for FRA:41L

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€54.30
Price
€51.18
GF Value